Effect of Pitavastatin on the coronary endothelial dysfunction after PCI with DES (Drug-eluting stent)

Not Applicable

• Conditions: Patients with coronary artery disease

• Registration Number: JPRN-UMIN000005489
• Lead Sponsor: Hiroshima University hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-22
• Study Completion: 2020-02-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1.A PCI target lesion with graft disease or in-stent restenosis 2.Patients who have skip lesion without PCI target lesion, and planed PCI within this examination. But it does not limit the PCI by a disease of the right coronary artery 3.Stent which is BMS to use for PCI 4.Malignant tumor in active phase 5.Patients who meet contraindication of LIVALO tablet below a)Patients who have hypersensitivity to LIVALO tablet b)Patients who have severe liver dysfunction or biliary atresia c)Patients who are being treated with cyclosporine d)Pregnant women, women suspected of being pregnant, or lactating women 6.Patients with hypersensitive to contrast media 7.Patients with liver dysfunction [ALT(GPT) 100 IU/L <=] 8.Patients undergoing dialysis 9.Patients with familial hypercholesterolemia 10.Patients who are ineligible in the opinion of the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A rate of change of Coronary blood flow by acetylcholine provocation

Secondary Outcome Measures

Name	Time	Method
1.The changes in vessel diameter on target vessel and non-target vessel by acetylcholine provocation 2.The changes in TC, LDL-C, TG, HDL-C, non-HDL-C, LDL-C/HDL-C, RLP-C and MDA-LDL 3.The Correlation between change in lipid profiles and change in Coronary blood flow by acetylcholine provocation 4.The Correlation between change in lipid profiles and change in coronary blood vessel diameter of target vessel and non-target vessel by acetylcholine provocation 5.Changes in inflammation marker (hs-CRP) 6.The Correlation between change in inflammation marker and change in Coronary blood flow by acetylcholine provocation 7.The Correlation between change in inflammation marker and change in coronary blood vessel diameter of target vessel and non-target vessel by acetylcholine provocation 8.The incidence rate of adverse event 9.The changes in laboratory values